BPC-157 Dosage Guide
Section titled “BPC-157 Dosage Guide”BPC-157 (Body Protection Compound-157) is a 15-amino acid peptide derived from human gastric juice. It demonstrates broad tissue-protective effects in preclinical models, including accelerate wound healing, gastrointestinal repair, and musculoskeletal recovery. No FDA-approved clinical indications exist; all dosing data derives from animal studies and preclinical research.
Molecular Properties
Section titled “Molecular Properties”| Property | Value |
|---|---|
| Sequence | GEPPPGKPADDAGLV |
| Molecular weight | 1,419.5 Da |
| Stability | Resistant to gastric acid (oral bioavailable) |
| Half-life | ~4 hours (estimated) |
| Solubility | Water-soluble |
Route-Dependent Dosing
Section titled “Route-Dependent Dosing”BPC-157 exhibits different pharmacokinetic profiles depending on administration route:
Oral Administration
Section titled “Oral Administration”Oral dosing exploits BPC-157’s gastric acid stability. The peptide survives first-pass metabolism and exerts local GI effects before systemic absorption.
| Parameter | Value |
|---|---|
| Bioavailability | Estimated 50–70% (GI local effects不受 first-pass影响) |
| Onset | 15–30 minutes |
| Duration | 4–6 hours |
| Frequency | 1–2 times daily |
Typical research doses:
| Indication | Dose Range | Frequency |
|---|---|---|
| GI protection | 10–50 µg/kg | 1–2× daily |
| Wound healing | 10–20 µg/kg | 1–2× daily |
| Musculoskeletal | 10–20 µg/kg | 1–2× daily |
| Neuroprotection | 10–20 µg/kg | 1–2× daily |
Injectable Administration (Subcutaneous)
Section titled “Injectable Administration (Subcutaneous)”Subcutaneous injection provides higher systemic bioavailability for non-GI applications.
| Parameter | Value |
|---|---|
| Bioavailability | ~90% |
| Onset | 5–15 minutes |
| Duration | 4–6 hours |
| Frequency | 1–2 times daily |
Typical research doses:
| Indication | Dose Range | Frequency |
|---|---|---|
| Tendon/ligament repair | 10–20 µg/kg | 1× daily |
| Muscle injury | 10–20 µg/kg | 1× daily |
| Bone healing | 10–20 µg/kg | 1× daily |
| Neuroprotection | 10–20 µg/kg | 1× daily |
Injectable Administration (Intraperitoneal)
Section titled “Injectable Administration (Intraperitoneal)”IP injection is the primary route in preclinical animal studies. Doses are not directly translatable to human research.
| Species | Typical Dose | Frequency |
|---|---|---|
| Rat | 10 µg/kg | 1× daily |
| Mouse | 10 µg/kg | 1× daily |
Concentration Calculations
Section titled “Concentration Calculations”Reconstitution Protocol
Section titled “Reconstitution Protocol”Standard reconstitution: 5 mg vial + 5 mL bacteriostatic water = 1 mg/mL
| Vial Mass | BAC Water Volume | Final Concentration |
|---|---|---|
| 5 mg | 5 mL | 1 mg/mL |
| 5 mg | 10 mL | 0.5 mg/mL |
| 5 mg | 2.5 mL | 2 mg/mL |
Dose Volume Calculation
Section titled “Dose Volume Calculation”Formula:
Volume (mL) = Dose (mg) ÷ Concentration (mg/mL)Example 1: 250 µg dose from 1 mg/mL solution:
Volume = 0.25 mg ÷ 1 mg/mL = 0.25 mL (25 units on U-100 syringe)Example 2: 500 µg dose from 1 mg/mL solution:
Volume = 0.5 mg ÷ 1 mg/mL = 0.5 mL (50 units on U-100 syringe)Dose Table (70 kg Subject)
Section titled “Dose Table (70 kg Subject)”| Target Dose | From 1 mg/mL | From 0.5 mg/mL | From 2 mg/mL |
|---|---|---|---|
| 10 µg/kg (700 µg) | 0.70 mL | 1.40 mL | 0.35 mL |
| 15 µg/kg (1050 µg) | 1.05 mL | 2.10 mL | 0.53 mL |
| 20 µg/kg (1400 µg) | 1.40 mL | 2.80 mL | 0.70 mL |
Injection Technique
Section titled “Injection Technique”Subcutaneous Administration
Section titled “Subcutaneous Administration”- Prepare workspace: Clean surface, sterile supplies
- Clean vial stopper: 70% isopyl alcohol swab
- Draw dose: Use 1 mL syringe with 25–30 gauge needle
- Pinch skin: Create skin fold at injection site
- Insert needle: 45–90 degree angle
- Inject slowly: Over 5–10 seconds
- Withdraw needle: Release skin fold
- Apply pressure: Brief gauze compression
Preferred Injection Sites
Section titled “Preferred Injection Sites”| Site | Absorption Rate | Comfort |
|---|---|---|
| Abdomen (2 inches from navel) | Fastest | Moderate |
| Thigh | Moderate | High |
| Upper arm | Moderate | Moderate |
| Buttock | Slowest | High |
Rotate injection sites to prevent lipodystrophy.
Storage and Stability
Section titled “Storage and Stability”| Parameter | Lyophilized | Reconstituted |
|---|---|---|
| Storage temperature | 2–8°C or −20°C | 2–8°C |
| Shelf life | 24 months (lyophilized) | 30 days |
| Light sensitivity | Protect from light | Protect from light |
| Freeze-thaw | Stable (lyophilized) | Do not freeze |
Preclinical Evidence Summary
Section titled “Preclinical Evidence Summary”| Model | Route | Dose | Outcome |
|---|---|---|---|
| Rat Achilles tendon | SC | 10 µg/kg/day | Enhanced healing, increased biomechanical strength |
| Rat colitis | Oral | 10 µg/kg/day | Reduced inflammation, restored mucosa |
| Rat brain injury | IP | 10 µg/kg/day | Improved neurological recovery |
| Rabbit ligament | SC | 10 µg/kg/day | Accelerated collagen maturation |
| Rat bone fracture | SC | 10 µg/kg/day | Enhanced callus formation |
Safety Profile
Section titled “Safety Profile”Preclinical observations:
- No adverse effects reported at doses up to 500 µg/kg in rats
- No genotoxicity, mutagenicity, or carcinogenicity observed
- No significant organ toxicity in 28-day repeated dose studies
- Gastric acid stability does not cause GI irritation
Limitations:
- No human clinical trial data
- Regulatory status: Investigational research chemical
- Not approved for human consumption or medical use
Internal Links
Section titled “Internal Links”- Peptide Reconstitution Calculator — Volume calculations
- BAC Water for Peptides — Diluent selection
- Peptide Stability — Degradation mechanisms
- Peptide Clinical Dosing — Clinical protocols
External References
Section titled “External References”- Sikiric P, et al. “BPC 157 and its role in wound healing, GI protection, and sports medicine.” Curr Pharm Des 2018;24:26-36.
- Chang CH, et al. “BPC 157: A novel peptide with broad pharmacological activity.” Peptides 2019;117:170075.